LEADER 01763nam  2200409   450 
001 9910707302003321
005 20160808073136.0
035   $a(CKB)5470000002464503
035   $a(OCoLC)956311075
035   $a(EXLCZ)995470000002464503
100   $a20160808d2016      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMedicare Part B, CMS should take additional steps to verify accuracy of data used to set payment rates for drugs : report to the Ranking Member, Committee on Ways and Means, House of Representatives
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2016.
215   $a1 online resource (iii, 35 pages) $ccolor illustrations
300   $aTitle from title screen (viewed on August 3, 2016).
300   $a"GAO-16-594."
300   $a"July 2016."
320   $aIncludes bibliographical references.
517   $aMedicare Part B, CMS should take additional steps to verify accuracy of data used to set payment rates for drugs 
606   $aElectronic data processing$zUnited States
606   $aDrugs$xPrices$zUnited States
606   $aMedicare$xEconomic aspects
615  0$aElectronic data processing
615  0$aDrugs$xPrices
615  0$aMedicare$xEconomic aspects.
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Ways and Means,
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707302003321
996   $aMedicare Part B, CMS should take additional steps to verify accuracy of data used to set payment rates for drugs : report to the Ranking Member, Committee on Ways and Means, House of Representatives$93311838
997   $aUNINA